The purpose of the study is to evaluate the routes and rate of elimination and recovery of total radioactivity (TRA) and characterize the Pharmacokinetic (PK) of VX-993 after a single oral dose of 14C-VX-993.
This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.)
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
8
Solution for Oral Administration.
Celerion - Lincoln
Lincoln, Nebraska, United States
Terminal Phase Rate Constant (λz) of VX-993 in Plasma
Time frame: From Day 1 up to Day 25
Area Under the Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUC0-tlast) of VX-993 in Plasma
Time frame: From Day 1 up to Day 25
Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of VX-993 in Plasma
Time frame: From Day 1 up to Day 25
Apparent Clearance (CL/F) of VX-993 in Plasma
Time frame: From Day 1 up to Day 25
Maximum Observed Plasma Concentration (Cmax) of VX-993 in Plasma
Time frame: From Day 1 up to Day 25
Time for VX-993 to Reach Maximum Concentration (Tmax) in Plasma
Time frame: From Day 1 up to Day 25
Apparent Volume of Distribution (Vz/F) (Based on the Terminal Phase) of VX-993 in Plasma
Time frame: From Day 1 up to Day 25
Terminal Phase Rate Constant (λz) of Total Radioactivity (TRA) in Whole blood and Plasma
Time frame: From Day 1 up to Day 25
Amount of Radioactivity Excreted (Ae) of TRA in Urine, Feces and Vomitus (if applicable)
Time frame: Pre dose up to Day 25
AUC0-tlast of TRA in Whole blood and Plasma
Time frame: From Day 1 up to Day 25
AUC0-inf of TRA in Whole blood and Plasma
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: From Day 1 up to Day 25
CL/F of TRA in Whole blood and Plasma
Time frame: From Day 1 up to Day 25
Renal Clearance (CLr) of TRA in Urine and Feces
Time frame: Pre dose up to Day 25
Cmax of TRA in Whole blood and Plasma
Time frame: From Day 1 up to Day 25
Fraction (percent) of Dose Excreted Unchanged in Urine of TRA
Time frame: Pre dose up to Day 25
Tmax of TRA in Whole blood and Plasma
Time frame: From Day 1 up to Day 25
Apparent Volume of Distribution (Based on the Terminal Phase) of TRA in Whole blood and Plasma
Time frame: From Day 1 up to Day 25
Amount of VX-993 and Metabolites, Expressed as a percent of TRA, in Plasma, Urine and Feces
Time frame: From Day 1 up to Day 25
Metabolite Profiling and Identification in Plasma, Urine, and Feces
Time frame: From Day 1 up to Day 25
Terminal Phase Rate Constant (λz) of VX-993 Metabolites in Plasma and Urine (if applicable)
Time frame: From Day 1 up to Day 25
Amount of radioactivity excreted (Ae) of VX-993 Metabolites in Urine and Feces
Time frame: Pre dose up to Day 25
AUC0-last of VX-993 Metabolites in Plasma
Time frame: From Day 1 up to Day 25
AUC0-inf of VX-993 Metabolites in Plasma
Time frame: From Day 1 up to Day 25
CL/F of VX-993 Metabolites in Plasma
Time frame: From Day 1 up to Day 25
CLr of VX-993 Metabolites in Urine
Time frame: From Day 1 up to Day 25
Cmax of VX-993 Metabolites in Plasma
Time frame: From Day 1 up to Day 25
Fraction (percent) of Dose Excreted Unchanged in Urine of VX-993 Metabolites
Time frame: Pre dose up to Day 25
Tmax of VX-993 Metabolites in Plasma
Time frame: Day 1 up to Day 25
Apparent Volume of Distribution (Based on the Terminal Phase) of VX-993 Metabolites in Plasma
Time frame: Day 1 up to Day 25
Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: Day 1 up to Day 35
Safety and Tolerability as Assessed by Number of Participants With Clinically Meaningful Findings in Columbia Suicide Severity Rating Scale (C-SSRS) Responses
Time frame: Pre-dose up to Day 35